. 2023 Jun 6;10:1161871. doi: 10.3389/fcvm.2023.1161871

Table 3.

HAVB-associated clinical differences between patients with HC and without HC.

	HAVB without HC (n = 417)	HAVB with HC (n = 49)	p-value
Onset of HAVB after TAVI, days	1 (0–3)	2 (1–4)	<0 . *001*
Transvenous pacer^a	277 (70.8)	20 (44.4)	<0 . *001*
Bradycardia-inducing medication^b^,^c	244 (62.4)	33 (76.7)	0.063
Post-TAVI delirium before onset of HAVB^d	18 (4.6)	11 (25.0)	<0 . *001*
PPI after TAVI, days	3 (1–6)	4 (2–6)	0.068

Continuous variables are depicted as median with interquartile range, categorical parameters are presented as numbers with percentages. Significant values are depicted in bold and italics.

HAVB, high-degree AV block; HR, hemodynamic compromise; PPI, permanent pacemaker implantation.

^{^a}

Information available in 391 pts without HC and 45 pts with HC.

^{^b}

Bradycardia-inducing medication defined as beta-blockers, non-dihydropyridine calcium-channel blocker (verapamil, diltiazem), digitalis, amiodarone and other anti-arrhythmic medication within the last 24 h before onset of HAVB.

^{^c}

Information available in 391 pts without HC and 43 pts with HC.

^{^d}

Information available in 406 pts without HC and 29 pts with HC.